In this study, we investigated the effect of an inducer of the NLRP3 inflammasome, Nigericin and an inhibitor of Caspase 1, VX765, on tumor progression in a panel of cancer cells, including A549 (lung cancer), MCF7 (breast cancer), PC3 (prostate cancer), SH-SY5Y (neuroblastoma) and U138MG (glioblastoma) cell lines. Here, CASP1 is linked to prostate carcinoma.